PMID: 15967086Jun 22, 2005Paper

Medullary thyroid cancer: medical management and follow-up

Current Treatment Options in Oncology
Amber Traugott, J F Moley


Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy that occurs in hereditary (25%) and sporadic (75%) clinical settings. MTC is present in all patients with the multiple endocrine neoplasia type 2 (MEN 2) syndromes. MTCs produce calcitonin, measurement of which indicates the presence of tumor in at-risk individuals and the effectiveness of therapy in treated patients. Surgery is the mainstay of therapy for primary and recurrent disease. Routine serial postoperative measurement of calcitonin levels should be done. Patients with elevated calcitonin levels should have imaging by computed tomography scan, magnetic resonance imaging, and/or fluorodeoxyglucose positron emission tomography to identify sites of recurrence and metastasis. The role of radiation therapy is not well defined. There is no effective systemic therapy for MTC at present. Activating mutations in a tyrosine kinase receptor gene are present in the majority of MTCs, and experience with tyrosine kinase inhibitors and other agents in the setting of clinical trials is critical for the identification of effective systemic treatment.


Jan 1, 1992·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·T D NguyenG Chaplain
Oct 15, 1991·Cancer·N A SamaanR A Lewis
Jan 1, 1990·Acta Oncologica·P GröhnM Jakobsson
Jan 1, 1990·Journal of Cancer Research and Clinical Oncology·H ScherüblR Ziegler
Jul 1, 1980·Clinics in Endocrinology and Metabolism·G W SizemoreJ A Carney
Oct 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F OrlandiA Angeli
Jan 1, 1995·Clinical Endocrinology·K Frank-RaueF Raue
Jul 1, 1993·Human Molecular Genetics·H Donis-KellerS A Wells
Jan 1, 1996·Journal of Pediatric Surgery·M A SkinnerS A Wells
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M JuweidD M Goldenberg
Mar 1, 1996·Endocrinology and Metabolism Clinics of North America·J D Brierley, R W Tsang
Jul 1, 1997·Surgical Oncology Clinics of North America·P A Treseler, O H Clark
Jul 29, 1998·Journal of Internal Medicine·J F MoleyS A Wells
Nov 3, 1998·European Journal of Nuclear Medicine·L BernàI Carrió
Jun 15, 2000·European Journal of Nuclear Medicine·K Brandt-MainzA Bockisch
Sep 28, 2000·European Journal of Nuclear Medicine·D J KwekkeboomE P Krenning
Mar 29, 2001·Thyroid : Official Journal of the American Thyroid Association·P S SinhaP Ryan
Nov 20, 2002·Cancer Immunology, Immunotherapy : CII·Matthias SchottJochen Seissler
Apr 8, 2004·Cancer Biotherapy & Radiopharmaceuticals·Lisa BodeiGiovanni Paganelli
May 6, 2004·The Journal of Clinical Endocrinology and Metabolism·K KaczirekB Niederle
May 8, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anton StiftJosef Friedl
Jul 9, 2004·Journal of the National Cancer Institute·Giuditta CuccuruFranco Zunino

❮ Previous
Next ❯


Jun 22, 2014·Current Problems in Cancer·Amir H Lebastchi, Glenda G Callender
Jun 23, 2011·Expert Review of Vaccines·Byram W Bridle
Dec 21, 2010·Seminars in Oncology·Susan C Pitt, Jeffrey F Moley
Sep 8, 2010·Current Problems in Surgery·Ismail JatoiMichael A Choti
Aug 4, 2007·Endocrinology and Metabolism Clinics of North America·Catherine Dinauer, Gary L Francis
Jun 16, 2009·Journal of Internal Medicine·W van VeelenC J M Lips
Aug 22, 2007·International Journal of Cancer. Journal International Du Cancer·Meera SrivastavaLukas Bubendorf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.